BridgeBio Oncology Therapeutics, Inc. Announces New Clinical Data for RAS and PI3Kα Programs
I'm PortAI, I can summarize articles.
BridgeBio Oncology Therapeutics, Inc. announced positive preliminary safety and antitumor data for its RAS and PI3Kα programs on January 7, 2026. Key highlights include a 65% overall response rate (ORR) for BBO-8520 in NSCLC patients with KRASG12C mutation, promising efficacy and safety when combined with pembrolizumab, and a partial response in pancreatic cancer with BBO-11818. BBO-10203 showed no hyperglycemia, leading to combination studies in CRC and BC. A company webcast is scheduled for January 7, 2026, at 8:30 a.m. ET.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments